InnoCare Pharma (SEHK:09969) Q4 2025 Earnings call March 25, 2026 08:30 AM ET Company ParticipantsCarrie Zhou - VP of Medical ResearchChen Chen - Executive Director and Head of China HealthcareJasmine Cui - Co-Founder, Chairwoman, and CEOJason Zhang - Head of Pharmacology and Translational MedicineRenbin Zhao - SVP of Medical Research and Clinical DevelopmentXiangyang Chen - CTOXin Fu - CFOConference Call ParticipantsZiyi Chen - China Healthcare AnalystNone - AnalystZiyi ChenGreat. Good morning and good eve ...

InnoCare Pharma (SEHK:09969) Q4 2025 Earnings call March 25, 2026 08:30 AM ET Speaker8Great. Good morning and good evening our global investors. Thank you for joining InnoCare 2025 annual results earnings call. This is Ziyi Chen, China Healthcare Analyst at Goldman Sachs. Before we kick off the session, I would like to highlight that this call is strictly for clients of Goldman Sachs and InnoCare only, and this conversation is not intended for media and is off the record. Participants will be removed on the ...

Group 1 - The Hang Seng Biotechnology Index (HSHKBIO) has seen a strong increase of 4.10%, with notable gains in constituent stocks such as Xintai Medical (02291) up 46.88%, Lepu Biopharma-B (02157) up 11.87%, and Innovent Biologics (09969) up 11.10% [1] - The Hang Seng Biotechnology ETF (513280) has risen by 2.80%, marking its third consecutive increase, with the latest price at 0.84 HKD. Over the past two weeks, the ETF has accumulated a rise of 3.27% [1] - The trading activity for the Hang Seng Biotechnology ETF has been active, with a turnover rate of 18.69% and a transaction volume of 46.885 million HKD, indicating robust market participation [1] Group 2 - The Hang Seng Biotechnology ETF has experienced a significant increase in shares, with a growth of 14 million shares over the past month, ranking it in the top third among comparable funds [3] - In terms of capital inflow, the ETF has seen net inflows on 15 out of the last 21 trading days, totaling 16.1235 million HKD [3] Group 3 - The pharmaceutical sector is showing a continuous upward recovery, with a focus on key innovative drug clinical data and milestone progress. Notable developments include the initiation of a Phase III clinical trial by Innovent Biologics for a drug targeting obstructive sleep apnea and the approval of a monoclonal antibody by CanSino Biologics [6] - The National Medical Products Administration has approved CanSino's monoclonal antibody injection for treating moderate to severe plaque psoriasis in adults [6] Group 4 - Hainan University has announced the release of its self-developed brain-computer interface (BCI) technology, marking a significant advancement in the field and enhancing China's capabilities in brain science research and medical applications [7] - The increase in tariffs on imports from the U.S. is expected to benefit domestic companies in the blood products and high-end medical device sectors, as well as in innovative drug development, promoting domestic substitutes [7] Group 5 - The Hang Seng Biotechnology ETF (513280) is noted for its low fee structure, with a management fee of only 0.15% per year, significantly lower than similar products, which could lead to better long-term returns for investors [8] - The ETF's composition includes a high proportion of innovative drugs at 66.4%, with a balanced distribution across various sectors, enhancing its investment potential [8]